




>>Entry Name: Sulfasalazine, INN

Synonym(s): 2-Hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]benzoic acid, 9CI. 5-[[p-(Pyridylsulfamoyl)phenyl]azo]salicylic acid, 8CI. 4-Hydroxy-4'-(2-pyridylsulfamoyl)azobenzene-3-carboxylic acid. **Salazosulfapyridine**, JAN. Sulphasalazine, BAN. Salicylazosulfapyridine. Salazopyrin. Azulfidine. Sulazine



CAS Registry Number: 599-79-1

Molecular Formula: C₁₈H₁₄N₄O₅S

Molecular Weight: 398.398

Accurate Mass: 398.068491

Percentage Composition: C 54.27%; H 3.54%; N 14.06%; O 20.08%; S 8.05%

Biological Use/Importance: Used in treatment of ulcerative colitis and arthritis

Physical Description: Yellow or brownish-yellow powder

Development Status: Approved 1980

Melting Point: Mp 240-245 dec.°

Solubility: Insol. Et₂O

Calculated Log P Data: Log P 3.83 (calc)

Hazard & Toxicity: Adverse therapeutic effects incl. headache, gastrointestinal disturbances, oligospermia, and haematological and hypersensitivity reactions. Human teratogenic effects also reported

Aldrich: 46084-2

Fluka: 86115

Sigma: S0883

References:

- Doraswamy, K.R. *et al.*, *J. Indian Chem. Soc.*, 1946, **23**, 278, (*synth*)
Kracmar, J. *et al.*, *Pharmazie*, 1975, **30**, 447, (*uv*)
McDonnell, J.P. *et al.*, *Anal. Profiles Drug Subst.*, 1976, **5**, 515, (*rev, synth, metab, anal*)
Peppercorn, M.A., *Ann. Intern. Med.*, 1984, **101**, 377, (*rev, pharmacol, tox, metab*)
Neumann, V.C. *et al.*, *J. R. Soc. Med.*, 1984, **77**, 169, (*rev, pharmacol*)
Hoult, J.R.S., *Drugs*, 1986, **32**, 18, (*rev*)
Negwer, M., *Organic-Chemical Drugs and their Synonyms*, 6th edn., *Akademie-Verlag*, 1987, 4658
Gaginella, T.S. *et al.*, *Dig. Dis. Sci.*, 1992, **37**, 801, (*rev*)
Martindale, The Extra Pharmacopoeia, 30th edn., *Pharmaceutical Press*, 1993, 906
Lewis, R.J., *Sax's Dangerous Properties of Industrial Materials*, 8th edn., *Van Nostrand Reinhold*, 1992, PPN750